Rybelsus

DRUG2 trials

Sponsors

Pfizer, Qilu Pharmaceutical Co., Ltd.

Conditions

Diabetes MellitusObesityType 2 Diabetes

Phase 2

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

TerminatedNCT05579977

PfizerDiabetes Mellitus, Obesity

Start: 2022-10-27End: 2023-09-22Updated: 2024-08-01

Phase 3

Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

Not yet recruitingNCT07487103

Qilu Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2026-05-01End: 2027-05-01Target: 478Updated: 2026-04-28

Related Papers

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Diabetes Obesity and Metabolism2024-10-1617 citations